Inhibition of CXCL5, CXCL13, XCL-1,and CCL2/MCP-1 during the cerebral ischemia/reperfusion (CI/R) phase of VaD holds promise as a therapeutic strategy to mitigate microglial activation and minimize neurological injury. Here, CCL2 is linked to brain ischemia.